

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: LYGDPO Page 1 of 3

(Induction Cycles 2 to 6)

DOCTOR'S O	RDERS	Ht	cm	Wt	kg	BSA	m²
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form							
DATE:		To be given:			Сус	le #:	
Date of Previous Cycl	e:						
☐ Delay treatment _ ☐ CBC & Diff Day 1		• •					
Day 1: May proceed with doses as written, if within 72 hours ANC <u>greater than or equal to</u> 1.0 x 10 ⁹ /L, platelets <u>greater</u> than or equal to 75 x 10 ⁹ /L, creatinine clearance <u>greater than or equal to</u> 60 mL/min							
Day 8: May proceed with doses as written, if within 48 hours ANC <u>greater than or equal to</u> 1.0 x 10 ⁹ /L, platelets <u>greater</u> than or equal to 75 x 10 ⁹ /L							
For split dose CISplatin only: Day 1: May proceed with doses as written, if within 72 hours ANC greater than or equal to 1.0 x 10 ⁹ /L, platelets greater than or equal to 75 x 10 ⁹ /L, creatinine clearance greater than or equal to 45 mL/min Day 8: May proceed with doses as written, if within 48 hours ANC greater than or equal to 1.0 x 10 ⁹ /L, platelets greater than or equal to 75 x 10 ⁹ /L, creatinine clearance greater than or equal to 45 mL/min							
Dose modification for:							
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm DAY 1 (and DAY 8 if split dose CISplatin being given): PREMEDICATIONS FOR gemcitabine, CISplatin, or CARBOplatin: dexamethasone 8 mg or 12 mg (select one) PO 30 to 60 minutes prior to treatment on Day 1 (and Day 8). If dexamethasone IV has been given the same day for the oBINutuzumab premedication, then omit dexamethasone PO.							
AND select ONE of the		aprepitant 125 mg PO 30 to 60 minutes prior to treatment, and condansetron 8 mg PO 30 to 60 minutes prior to treatment					
following:	□ r	netupitant-palonosetron 300 mg-0.5 mg PO 30 to 60 minutes prior to treatment					
		ondansetron 8 mg PO 30 to 60 minutes prior to treatment					
If additional antiemetic required: ☐ OLANZapine ☐ 2.5 mg or ☐ 5 mg or ☐ 10 mg (select one) PO 30 to 60 minutes prior to treatment PREMEDICATIONS FOR oBINutuzumab INFUSION:							
☐ If previous oBINutuzumab reaction was Grade 3, or if lymphocyte count greater than 25 x 10 ⁹ /L before Day 1 of current cycle, then 60 minutes prior to infusion: dexamethasone 20 mg IV							
30 minutes prior to infusion: acetaminophen 650 to 975 mg PO and diphenhydrAMINE 50 mg PO							
Continued on page 2						_	
DOCTOR'S SIGNATURE:					s	IGNATURE:	
						U	C:



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: LYGDPO Page 2 of 3 (Induction Cycles 2 to 6)

DATE:						
PREMEDICATIONS, continued:						
DAY 8 (unless split dose CISplatin being given)						
PREMEDICATIONS FOR gemcitabine						
prochlorperazine 10 mg PO prior to gemcitabine						
☐ Other						
PRE-HYDRATION:						
1000 mL NS IV over 1 hour prior to CISplatin on Day 1 (and Day 8 if split dose CISplatin g	iven)					
** Have Hypersensitivity Reaction Tray and Protocol Available**						
TREATMENT:						
Days 1 to 4:						
dexamethasone 40 mg PO daily in AM on Days 1 to 4.						
Day 1: gemcitabine 1000 mg/m² x BSA =mg Dose Modification:% =mg/m² x BSA =mg IV in 250 mL NS over 30 minutes on Day 1 (and Day 8- see next page) CISplatin 75 mg/m² x BSA =mg Dose Modification:% =mg/m² x BSA =mg IV with 20 mEq potassium chloride, 1g magnesium sulfate, and 30 g mannitol in 500 mL NS over 1 hour on Day 1 only. OR (only split CISplatin Day 1 and 8 if creatinine clearance on Day 1 less than 60 mL/min) CISplatin 37.5 mg/m² x BSA =mg Dose Modification:% =mg/m² x BSA =mg IV with 20 mEq potassium chloride, 1g magnesium sulfate, and 30 g mannitol in 500 mL NS over 1 hour on Day 1 (and Day 8- see next page)						
CARBOplatin AUC 5 x (GFR + 25) = mg (maximum 800mg) Dose Modification: % = mg IV in 100 to 250 mL NS over 30 minutes on Day 1 only oBINutuzumab 1000 mg IV in 250 mL NS on Day 1. If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate 100 mg/h or faster: Start at 100 mg/h. Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table.						
Continued on page 3						
DOCTOR'S SIGNATURE:	SIGNATURE:					
	UC:					



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: LYGDPO Page 3 of 3 (Induction Cycles 2 to 6)

DATE:	
TREATMENT, continued:	
Day 8: gemcitabine 1000 mg/m² x BSA =mg Dose Modification:% =mg/m² x BSA =mg IV in 250 mL NS over 30 minutes on Day 8	
If split dose CISplatin:	
CISplatin 37.5 mg/m² x BSA =mg Dose Modification:% =mg/m² x BSA =mg IV with 20 mEq potassium chloride, 1g magnesium sulfate, and 30 g mannitol in 500 mL NS	over 1 hour on Day 8
RETURN APPOINTMENT ORDERS	
Return in <u>three</u> weeks for Doctor and Cycle Book treatment on Day 1 and Day 8. Cycle 6: Return in <u>two</u> months (calculate in months, not weeks) for Doctor and Cycle 7. Book treatment for Day 1 only.	
CBC & Diff, creatinine prior to each cycle	
CBC & Diff on Day 8	
Creatinine on Day 8 if split dose CISplatin ordered	
If clinically indicated:	
☐ ALT ☐ HBV viral load	
☐ Other tests:	
☐ Consults:	
\square See general orders sheet for additional requests.	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC: